Last reviewed · How we verify

NCT04371692: EXPOCOVIA

Prevalence of COVID-19 Infection Among HCW in a French University Hospital

Completed Last updated 23 April 2021
What this trial tests

trial testing self-administered questionnaire in Sars-CoV2 in 900 participants. Completed in 9 July 2020.

Timeline
15 June 2020
Primary endpoint
9 July 2020
9 July 2020

Quick facts

Lead sponsorUniversity Hospital, Lille
StatusCompleted
Study typeOBSERVATIONAL
Enrollment900
Start date15 June 2020
Primary completion9 July 2020
Estimated completion9 July 2020
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Lille

Who can join

18 and older, any sex, with Sars-CoV2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to determine the prevalence of SARS-Cov2 infection among health care workers exposed of Lille University Hospital, to describe its evolution during the epidemic taking into account the influence of occupational and environmental exposure determinants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of self-administered questionnaire

Trials testing the same drug.

Other recruiting trials for Sars-CoV2

Currently open trials in the same condition.

Other University Hospital, Lille trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04371692.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing